Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
PETHEMA Foundation
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
Assistance Publique - Hôpitaux de Paris
M.D. Anderson Cancer Center
Stanford University
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
Karolinska University Hospital
The First Affiliated Hospital of Soochow University
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Goethe University
First Affiliated Hospital of Zhejiang University
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
University Hospital Schleswig-Holstein
Cedars-Sinai Medical Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
First Affiliated Hospital of Zhejiang University
Stichting Hemato-Oncologie voor Volwassenen Nederland
Institute of Hematology and Blood Transfusion, Czech Republic
The First Affiliated Hospital of Soochow University
Ludwig-Maximilians - University of Munich
St. Anna Kinderkrebsforschung
Zhejiang University
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Seoul National University Hospital
University of British Columbia
Assistance Publique - Hôpitaux de Paris
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Gruppo Italiano Malattie EMatologiche dell'Adulto